Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safety in rea...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	BMC neurology Ročník 19; číslo 1; s. 159 - 9
Hlavní autori:	Zecca, Chiara, Disanto, Giulio, Sacco, Rosaria, Riccitelli, Gianna C., Gobbi, Claudio
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 12.07.2019 BioMed Central Ltd BMC
Predmet:	Biological response modifiers CIS Comorbidity Demyelinating diseases Dosage and administration Drug approval Drug therapy Glatiramer acetate Interferon Medical records Medicine Medicine & Public Health Multiple sclerosis Neurochemistry Neurology Neurosurgery Patient monitoring equipment Patient outcomes Prescription writing Relapsing remitting Research Article Therapy Switzerland Glatiramer acetate Relapsing remitting Therapy Multiple sclerosis GA CIS
ISSN:	1471-2377, 1471-2377
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!